论文部分内容阅读
万乃洛韦(valaciclovir)是阿昔洛韦的L-缬氨酰酯,口服后迅速、几乎完全转变为阿昔洛韦,生物利用度是口服阿昔洛韦的3～4倍。该药对单纯疱疹病毒(HSV)急性或复发性感染的疗效与阿昔洛韦相似,但用药更方便,服药次数减少。该研究以万乃洛韦每日1次给药,观察其抑制生殖器HSV感染复发的疗效,并评价长程应用万乃洛韦的安全性。 采用多中心、随机、双盲、安慰剂对照临床
Valaciclovir, an acyclovir-based L-valyl ester, is rapidly and almost completely converted to acyclovir after oral administration. Its bioavailability is 3 to 4 times that of acyclovir. This medicine has similar curative effect on acyclovir to acute and recurrent infections of herpes simplex virus (HSV), but it is more convenient and less time consuming. The study was administered once-a-day once daily with valacyclovir to observe its efficacy in inhibiting the recurrence of genital HSV infection and to evaluate the safety of long-term use of valacyclovir. A multicenter, randomized, double-blind, placebo-controlled clinical trial was performed